{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:18:38Z","timestamp":1778602718099,"version":"3.51.4"},"reference-count":20,"publisher":"FapUNIFESP (SciELO)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Cir. Bras."],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:p>PURPOSE: To compare the frequency of conjunctival HLA-DR expression (a surrogate marker for inflammation) in eyes treated with topical prostaglandin analogues versus eyes treated with other topical antiglaucomatous drugs. METHODS: Patients diagnosed with primary open-angle glaucoma presenting indication for trabeculectomy were divided in groups according to the use or not of prostaglandin analogues. All subjects were treated with the maximum tolerated dose of antiglaucomatous drugs until the date of the surgery. At the beginning of the surgical procedure, a 5 x 5 mm biopsy of the bulbar conjunctiva was collected, incubated with monoclonal anti-HLA-DR antibody and processed for histological analysis. RESULTS: Of the 31 eyes included (31 patients), 25 were under topical prostaglandin analogues (Group 1) and six under other topical pharmacological agents (Group 2). Fourteen eyes of Group 1 (56%) and three of Group 2 (50 %) were positive for the inflammatory marker HLA-DR (P=1.0). The percentage of stained cells ranged from 15.49 to 48.09% (median: 27.61) in Group 1, and from 18.35 to 28 (median: 20.71) in Group 2, with no differences statistically significant (p=0.33). CONCLUSION: The use of prostaglandin analogues did not increase conjunctival expression of HLA-DR compared to other topical antiglaucomatous agents.<\/jats:p>","DOI":"10.1590\/s0102-86502012001000011","type":"journal-article","created":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T03:00:59Z","timestamp":1349060459000},"page":"732-735","source":"Crossref","is-referenced-by-count":6,"title":["Conjunctival inflammation in patients under topical glaucoma treatment with indication to surgery"],"prefix":"10.1590","volume":"27","author":[{"given":"Jo\u00e3o Marcello","family":"Furtado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayter Silva","family":"Paula","sequence":"additional","affiliation":[{"name":"USP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edson Garcia","family":"Soares","sequence":"additional","affiliation":[{"name":"USP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neifi Hassam Saloum","family":"Dhegaide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Melani","family":"Rocha","sequence":"additional","affiliation":[{"name":"USP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Donadi","sequence":"additional","affiliation":[{"name":"USP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria de Lourdes Veronese","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"USP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley HA","year":"2006","journal-title":"Br J Ophthalmol."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl A","year":"2002","journal-title":"Arch Ophthalmol."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/IJG.0b013e3181e0791c","article-title":"Efficiency of glaucoma drug regulation in 5 European countries: a 1995-2006 longitudinal prescription analysis","volume":"20","author":"De Natale R","journal-title":"J Glaucoma,"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00061198-200312000-00006","article-title":"Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects","volume":"12","author":"Stewart WC","year":"2003","journal-title":"J Glaucoma."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0002-9394(02)01980-3","article-title":"Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost","volume":"135","author":"Stewart WC","year":"2003","journal-title":"Am J Ophthalmol."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ajo.2006.02.056","article-title":"Effects of topical antiglaucoma application on conjunctival impression cytology specimens","volume":"142","author":"Hong S","year":"2006","journal-title":"Am J Ophthalmol."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000059624","article-title":"Ocular surface changes induced by topical antiglaucoma monotherapy","volume":"216","author":"Cvenkel B","year":"2002","journal-title":"Ophthalmologica."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/108076802317233162","article-title":"HLA-DR expression in conjunctival cells after latanoprost","volume":"18","author":"Guglielminetti E","year":"2002","journal-title":"J Ocul Pharmacol Ther."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1167\/iovs.03-1067","article-title":"Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study","volume":"45","author":"Pisella PJ","year":"2004","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ophtha.2007.01.036","article-title":"The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways","volume":"115","author":"Baudouin C","year":"2008","journal-title":"Ophthalmology."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/archopht.1994.01090230060021","article-title":"Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery","volume":"112","author":"Broadway DC","year":"1994","journal-title":"Arch Ophthalmol."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/IJG.0b013e31818153f4","article-title":"Immunohistochemical expression of HLA-DR in the conjunctiva of patients under topical prostaglandin analogs treatment","volume":"18","author":"Rodrigues Mde L","year":"2009","journal-title":"J Glaucoma."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/BF00166608","article-title":"Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: an immunohistochemical and ultrastructural study","volume":"233","author":"Nuzzi R","year":"1995","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/bjo.84.6.648","article-title":"Conjunctival epithelium expression of HLA-DR in glaucoma patients and its influence on the outcome of filtration surgery","volume":"84","author":"Ihan A","year":"2000","journal-title":"Br J Ophthalmol."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.ophtha.2004.06.023","article-title":"Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term","volume":"111","author":"Baudouin C","year":"2004","journal-title":"Ophthalmology."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1167\/iovs.04-1331","article-title":"In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells","volume":"46","author":"Guenoun JM","year":"2005","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1755-3768.2010.01907.x","article-title":"Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication","volume":"88","author":"Uusitalo H","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"ref18","first-page":"299","article-title":"Immunohistochemical HLA-DR antigen expression with lymphocyte subsets and proliferative activity in pterygium","volume":"16","author":"Tsironi S","year":"2002","journal-title":"In Vivo."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0019-509X.12345","article-title":"Affordable image analysis using NIH Image\/ImageJ","volume":"41","author":"Girish V","year":"2004","journal-title":"Indian J Cancer."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin C","journal-title":"Prog Retin Eye Res."}],"container-title":["Acta Cirurgica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/acb\/v27n10\/a11v27n10.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T22:43:24Z","timestamp":1714430604000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0102-86502012001000011&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0102-86502012001000011"],"URL":"https:\/\/doi.org\/10.1590\/s0102-86502012001000011","relation":{},"ISSN":["0102-8650"],"issn-type":[{"value":"0102-8650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}